CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and
pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel
in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment
option.